NCT00689767终止不适用
COronary Native Artery First in Man Investigation of ISA 247 Elution to Prevent Restenotic Mechanisms
适应症
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 103
- 试验地点
- 13
- 主要终点
- Late Lumen Loss
研究概览
简要总结
This First In Man study is a prospective, multicentre, single blind, randomized, controlled clinical trial of the CINATRA™ ISA 247 Coated Coronary Stent System as compared to the CINATRA™ Coronary Stent System. The study will enroll up to 100 evaluable patients at up to 7 sites. Clinical follow up will occur at 1 month, 6 months, and 1, 2, 3, 4 and 5 years post procedure. Repeat angiography and IVUS will be performed at the 6 month follow up time point for all subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with stable angina pectoris (Canadian Cardiovascular Society 1, 2, 3) or unstable angina pectoris with documented ischemia (CCS 4, Braunwald Class IB-C, IIB-C or IIIB-C), or patients with documented silent ischemia.
- •Patients who are eligible for coronary revascularization (percutanous angioplasty).
- •Acceptable candidates for coronary artery bypass grafting (CABG).
- •Patients with de novo lesion in a native coronary artery >50% and <100% stenosis.
- •NOTE: Treatment of lesions in a non-target vessel is up to the investigator's discretion (max. two-vessel-disease).
- •ONLY a bare metal stent (no drug eluting stent) can be used for this treatment. Treatment of any non-target vessel lesions must be successfully completed before enrolling patient and placing study stent.
- •The target lesion must be a maximum length of 13 mm (visual estimate) and able to be covered by one stent.
- •The reference diameter of the target lesion must be 3.0 mm by visual estimate.
- •Left ventricular ejection fraction of >30%.
- •Patients willing to provide written informed consent prior to participation and willing and able to participate in all follow-up evaluations.
排除标准
- •Patients under the age of 18 or unable to give informed consent.
- •Women who are pregnant. Women of child bearing potential must have a negative pregnancy test within 7 days prior to enrollment and utilize reliable contraception at a minimum until after the angiographic follow up.
- •Patients who previously participated in this study.
- •Patient is currently participating in an investigational drug or device study that has not completed the primary endpoint or that clinically interferes with the current study endpoints.
- •NOTE: Trials requiring extended follow-up for products that were investigational, but have since become commercially available, are not considered investigational trials.
- •Life expectancy of less than 12 months or factors making clinical and/or angiographic follow-up difficult (no fixed address, etc.).
- •Patients who intend to have a major surgical intervention within 6 months of enrollment in the study.
- •Patients with new ST elevation within 48 hours prior to stenting.
- •Braunwald Class IA, IIA and IIIA angina pectoris.
- •Patients with a contraindication to an emergency coronary bypass surgery.
- •Patients who had previous Coronary Artery Bypass Surgery (CABG).
- •Any individual who may refuse a blood transfusion.
- •Serum creatinine >3.0 mg/dL.
- •Platelet count <100,000 cells/mm³.
- •Patients with intolerance or contraindication to acetylsalicylic acid (aspirin), heparin, cyclosporin or cyclosporine derivative, clopidogrel or ticlopidine drug therapy.
- •Patients with contrast agent hypersensitivity that cannot be adequately pre-medicated.
- •Patients who have a stent anywhere within the target vessel.
- •Any planned interventional treatment of any vessel post study procedure.
- •Exclusion Criteria Related to Angiography
- •Patients with previous PCI of the same segment (i.e. no restenotic lesions).
- •Previous interventional procedure (less than 6 months) anywhere within the target vessel;
- •Target lesion is located in or supplied by an arterial or venous bypass graft.
- •Target lesion involves a side branch >2.0mm in diameter.
- •Ostial target lesion (within 3.0mm of vessel origin).
- •Target vessel has evidence of thrombus or is excessively tortuous that makes it unsuitable for proper stent delivery and deployment .
- •Patients with total occlusions (TIMI 0).
- •Significant (>50%) stenosis proximal or distal to the target lesion that might require revascularization or impede run off.
- •Target lesion requires treatment with a device other than the predilatation balloon prior to stent placement (including but not limited to, directional coronary atherectomy, excimer laser, rotational atherectomy, cutting balloon etc.).
结局指标
主要结局
Late Lumen Loss
时间窗: 6 months
次要结局
未报告次要终点
研究者
研究点 (13)
Loading locations...
相似试验
尚未招募
1 期
PRECICE 8.5mm First in Man Study - Intramedullary Limb Lengthening for Patients with a Unilateral Leg Length Discrepancyimb length discrepancyLimb length discrepancyMusculoskeletal - Other muscular and skeletal disordersACTRN12613000649718Ellipse Technologies, Inc.10
进行中（未招募）
不适用
Future Cardia™ Insertable Cardiac Monitor in Subjects With Paroxysmal Atrial Fibrillation (First-in-Human Study)Arrhythmias, CardiacBradycardiaAsystoleAtrial FibrillationVentricular TachycardiaNCT06167434Future Cardia, Inc30
招募中
不适用
First In Human Study to Assess Safety and Efficacy of the ChampioNIR™ Drug Eluting Peripheral Stent in the Treatment of Patients With Superficial Femoral Artery Disease and/or Proximal Popliteal Artery DiseaseSuperficial Femoral Artery StenosisPopliteal Artery StenosisNCT06410313Medinol Ltd.30
招募中
不适用
First in Human Study to Assess the Safety and the Efficacy of an Implantable Nitinol Device in the Treatment of KeratoconusKeratoconusNCT06451718Fundacio De Recerca Del Instituto De Microcirugia Ocular12
已完成
不适用
Stationary cycling versus walking: a comparison of exercise modalities following coronary artery bypass graft surgeryCoronary artery bypass graft surgeryCardiovascular - Coronary heart diseaseACTRN12608000359336Griffith University54